Business
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
LA JOLLA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the
About this update from Medicinova, Inc.
[{"type":"text","content":"LA JOLLA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s Chief Medical Officer, Kazuko Matsuda, MD PhD MPH, presented positive results from a subgroup analysis of the completed Phase 2 clinical trial which evaluated MN-001 (tipelukast) for the treatment of hypertriglyceridemia at the International Diabetes Federation (IDF) World Diabetes Congress 2022 held online December 5 - 8, 2022. In the completed Phase 2 study, MN-001 (tipelukast) significantly reduced serum triglycerides in participants with non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia (HTG). Subsequent in vitro results revealed that MN-001 (tipelukast) downregulated CD36 and upregulated ABCG1 mRNA expression, both of which are highly associated with Type 2 diabetes mellitus (T2DM). Hypothesizing that MN-001 (tipelukast) might be more effective at reducing serum triglycerides in participants with a dual diagnosis of NAFLD and Type 2 diabetes mellitus (T2DM), a subgroup analysis was conducted in participants with and without T2DM. In the presentation entitled, “Improvement of Serum Lipid Panel by Tipelukast (MN-001) in Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease Patients\" (Abstract #LI2022-1192) the following results were announced: Compared to subjects without T2DM, the T2DM group showed a greater reduction in serum triglyceride levels at Week 8 (50.8% reduction for with T2DM versus 17.8% reduction for without T2DM, p=0.098).Mean HDL increase was significantly greater in subjects with T2DM than subjects without T2DM at Week 8 (15.8% versus 1.0%, p","length":2315,"tagName":"div"}]